TOMBOLINI, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 1.122
AS - Asia 562
EU - Europa 536
SA - Sud America 127
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 2.369
Nazione #
US - Stati Uniti d'America 1.094
SG - Singapore 327
IE - Irlanda 169
BR - Brasile 114
CN - Cina 107
DE - Germania 92
SE - Svezia 57
RU - Federazione Russa 52
IT - Italia 38
HK - Hong Kong 35
GB - Regno Unito 29
VN - Vietnam 29
UA - Ucraina 24
CA - Canada 20
FI - Finlandia 20
TR - Turchia 16
BE - Belgio 13
FR - Francia 12
ES - Italia 11
IN - India 11
ZA - Sudafrica 10
AR - Argentina 7
BD - Bangladesh 6
CZ - Repubblica Ceca 6
IQ - Iraq 5
JP - Giappone 5
MX - Messico 5
PL - Polonia 5
AE - Emirati Arabi Uniti 4
AU - Australia 3
EU - Europa 3
LT - Lituania 3
PH - Filippine 3
PK - Pakistan 3
ID - Indonesia 2
MA - Marocco 2
NL - Olanda 2
UY - Uruguay 2
AT - Austria 1
BW - Botswana 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
ET - Etiopia 1
GY - Guiana 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.369
Città #
Chandler 192
Singapore 171
Dublin 169
Dallas 164
Jacksonville 95
Ashburn 75
Santa Clara 47
Ann Arbor 45
New York 38
Munich 37
Hong Kong 35
Boardman 32
Los Angeles 23
Beijing 22
Wilmington 21
Lawrence 20
Princeton 20
The Dalles 18
Bremen 15
São Paulo 15
Brussels 13
Columbus 13
Hanoi 12
Nanjing 12
Helsinki 11
Izmir 10
Moscow 8
Rome 8
Stockholm 8
Woodbridge 8
Orem 7
Turku 7
Brno 6
Brooklyn 6
Changsha 6
Johannesburg 6
L'aquila 6
San Mateo 6
Seattle 6
Shenyang 6
Atlanta 5
Chennai 5
Council Bluffs 5
Des Moines 5
Falls Church 5
Grafing 5
Kunming 5
Montreal 5
Warsaw 5
Belo Horizonte 4
Berlin 4
Denver 4
Falkenstein 4
Frankfurt am Main 4
Haiphong 4
Houston 4
Milan 4
Mountain View 4
Nanchang 4
Phoenix 4
Poplar 4
Shanghai 4
Tokyo 4
Toronto 4
Washington 4
Boston 3
Guangzhou 3
Ho Chi Minh City 3
Manchester 3
Mexico City 3
Norwalk 3
San Francisco 3
Ankara 2
Baghdad 2
Cape Town 2
Charlotte 2
Chicago 2
Curitiba 2
Da Nang 2
Dearborn 2
Düsseldorf 2
Hanover 2
Hebei 2
Hefei 2
Lanzhou 2
London 2
Madrid 2
Montevideo 2
Mumbai 2
New Delhi 2
Ottawa 2
Redwood City 2
Salvador 2
Santo André 2
Secaucus 2
São Bernardo do Campo 2
São José 2
Tappahannock 2
Thái Bình 2
Tianjin 2
Totale 1.605
Nome #
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma 178
Moderate hypofractionation in patients with low-risk prostate cancer: Long-term outcomes 166
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells 148
Clinically relevant radioresistant rhabdomyosarcoma cell lines: Functional, molecular and immune-related characterization 129
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells 126
New approaches in glioblastoma multiforme: The potential role of immune-check point inhibitors 125
Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines in Vitro and in Vivo 121
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results 117
Correction: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma (Journal of Hematology and Oncology (2018) 11(32) DOI: 10.1186/s13045-018-0576-6) 112
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo 109
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma 108
Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation 108
Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program 107
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines 106
Ms−275 (Entinostat) promotes radio-sensitivity in pax3-foxo1 rhabdomyosarcoma cells 104
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma (Journal of Cancer Research and Clinical Oncology, (2019), 145, 2, (393-409), 10.1007/s00432-018-2800-8) 103
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis 102
Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype 93
Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan 93
Sinonasal Undifferentiated Carcinoma in a Patient Previously Treated for an Intestinal-Type Adenocarcinoma: Metachronous Neoplasms or Recurrence of a Different Tumor Type? 76
Resilience in Radiotherapy Services During the COVID-19 Emergency: Collaboration Between the Regional Radiation Oncology Departments of Lazio, Abruzzo and Molise 43
Targeted molecular therapy in glioblastoma 34
Totale 2.408
Categoria #
all - tutte 10.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.113


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 4 21 1 19 8 25 5
2021/2022144 7 1 29 9 3 9 7 7 18 6 8 40
2022/2023491 30 42 6 80 33 52 0 24 200 6 12 6
2023/2024138 6 14 11 5 6 60 9 2 0 5 6 14
2024/2025629 18 10 30 60 89 69 82 48 115 19 50 39
2025/2026662 69 88 150 160 143 52 0 0 0 0 0 0
Totale 2.408